How Marco Pharma International Preserves German Homeopathic Traditions in America 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
MENLO PARK, Calif., Feb. 15, 2018 -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report its 2017 financial results and provide a corporate update on
February 22, 2018. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Conference Call Information
To participate, dial 1-800-289-0459 from the United States or 1-323-794-2558 internationally approximately 10 minutes before the start of the call. The passcode is 094798.
A replay will be available through March 8, 2018 at 1-888-203-1112 from the United States and 1-719-457-0820 internationally. The passcode will be 1581123.
About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym is the company’s first FDA-approved medication. Corcept has a large portfolio of proprietary compounds that selectively modulate the effects of cortisol but not progesterone. Corcept owns extensive United States and foreign intellectual property covering the use of cortisol modulators in the treatment of a wide variety of serious disorders, including Cushing’s syndrome. It also holds composition of matter patents covering its selective cortisol modulators.
CONTACT:
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783
[email protected]
www.corcept.com
